Epix lands drug-discovery partner

Article

Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry

Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry laboratories owned by NeoGenesis that enable the rapid screening of compounds that could be used to form new products. Epix hopes the deal will enable it to find new advanced MRI contrast agents.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
New Echocardiography Research Suggests Emerging Marker for Cardiomyopathy Detection in Patients with Duchenne Muscular Dystrophy
© 2025 MJH Life Sciences

All rights reserved.